Wed, May 8, 2024
[Archive]
Volume 28, Issue 1 (Winter 2024)
2024, 28(1): 41-48 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rafati P, Jafarzade J, Hoseinnejad A, Khalilpour A, Taghizadeh Armaki M, Kermani F. Investigating the Effectiveness of Spirocyclopropane-Oxindole Derivatives on Clinical Isolates of Candida albicans. Hormozgan Medical Journal 2024; 28 (1) :41-48
URL: http://hmj.hums.ac.ir/article-1-2731-en.html
URL: http://hmj.hums.ac.ir/article-1-2731-en.html
Pouria Rafati 
, Jalal Jafarzade , Akbar Hoseinnejad , Asieh Khalilpour , Mojtaba Taghizadeh Armaki * , Firoozeh Kermani
, Jalal Jafarzade , Akbar Hoseinnejad , Asieh Khalilpour , Mojtaba Taghizadeh Armaki * , Firoozeh Kermani
Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Abstract: (104 Views)
Objectives: Given the spread of azole resistance in Candida albicans (C. albicans), searching for new potent compounds, such as spirocyclopropane-oxindole derivatives is important. This study evaluates the antifungal susceptibility of spirocyclopropane-oxindole derivatives on clinical isolates of C. albicans.
Methods: Antifungal susceptibility of 50 clinical isolates of C. albicans to spirocyclopropane-oxindole derivatives (4a, 4b, and 4c), nystatin, and fluconazole were evaluated according to Clinical Laboratory Standards Institute (M27-S4) guidelines. The medicinal dilution range of the compounds, fluconazole, and nystatin was 0.256 to 128, 0.128 to 64, and 0.032 to 16 μg/mL, respectively. The minimum inhibitory concentration (MIC) was defined as the concentration that caused at least 50% growth inhibition compared to the positive control. Statistical analysis was performed using the SPSS software, version 20. The significance level was set at P≤0.05.
Results: There was a significant difference between the MIC values of spirocyclopropane-oxindole derivatives (4a, 4b, and 4c), nystatin, and fluconazole against C. albicans. The comparison of the MICs of the spirocyclopropane-oxindole derivatives (4a, 4b, and 4c) against C. albicans showed that derivative 4a had a lower MIC50 (8 μg/mL), MIC90 (16 μg/mL), and Geometric (G) Mean (10.126) than derivatives 4b (MIC50=64, MIC90=128, G Mean=76.638), and 4c (MIC50=64, MIC90=128, G Mean=60.547).
Discussion: Antifungal effects of spirocyclopropane-oxindole derivatives (4a, 4b, and 4c) on C. albicans isolates were significantly less than nystatin and fluconazole. Therefore, with structural changes, the antifungal effects of these compounds will increase.
Methods: Antifungal susceptibility of 50 clinical isolates of C. albicans to spirocyclopropane-oxindole derivatives (4a, 4b, and 4c), nystatin, and fluconazole were evaluated according to Clinical Laboratory Standards Institute (M27-S4) guidelines. The medicinal dilution range of the compounds, fluconazole, and nystatin was 0.256 to 128, 0.128 to 64, and 0.032 to 16 μg/mL, respectively. The minimum inhibitory concentration (MIC) was defined as the concentration that caused at least 50% growth inhibition compared to the positive control. Statistical analysis was performed using the SPSS software, version 20. The significance level was set at P≤0.05.
Results: There was a significant difference between the MIC values of spirocyclopropane-oxindole derivatives (4a, 4b, and 4c), nystatin, and fluconazole against C. albicans. The comparison of the MICs of the spirocyclopropane-oxindole derivatives (4a, 4b, and 4c) against C. albicans showed that derivative 4a had a lower MIC50 (8 μg/mL), MIC90 (16 μg/mL), and Geometric (G) Mean (10.126) than derivatives 4b (MIC50=64, MIC90=128, G Mean=76.638), and 4c (MIC50=64, MIC90=128, G Mean=60.547).
Discussion: Antifungal effects of spirocyclopropane-oxindole derivatives (4a, 4b, and 4c) on C. albicans isolates were significantly less than nystatin and fluconazole. Therefore, with structural changes, the antifungal effects of these compounds will increase.
Type of Study: Research |
Subject:
General
Received: 2023/07/23 | Accepted: 2023/09/29 | Published: 2024/01/1
Received: 2023/07/23 | Accepted: 2023/09/29 | Published: 2024/01/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
